ZOTANSE13 February 2025

Zota Health Care LImited has informed the Exchange about Investor Presentation

Zota Health Care LImited

February 13, 2025

To, The Manager Listing Department, The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Investor Presentation

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject we, Zota Health Care Limited are submitting herewith enclosed the Investor Presentation.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited

Ashvin Variya (Company Secretary & Compliance Officer) Place: Surat

Encl: a/a

Registered Office: Zota House, 2/896, Hira Modi Street, Sagrampura, Surat-395002 Ph: +91 261 2331601 Email: info@zotahealthcare.com Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

INDIA’S LARGEST PRIVATE GENERIC PHARMACY RETAIL CHAIN

F e b r u a r y 2 0 2 5

Zota Health Care Limited I nv e s t o r P r e s e n t a t i o n

Safe Harbour

This presentation has been prepared by the Zota Health Care Limited (the “Company”) only for information purpose to the stakeholders and does not contain any offer or invitation to subscribe the securities of the Company. No offering of securities shall be made except by means of offer documents.

This presentation has been prepared on the basis of information and data available with the Company consider reliable. This presentation may not contain all the information that you may consider material. Any liability in respect of the content of or any omission from this presentation is expressly excluded.

Stakeholders are advised to compare the data provided in the presentation with the full financial results available on the website of the Company as well as on website of NSE.

This presentation contains “forward-looking statements”, including “future oriented financial information” and “financial outlook”. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainty. Actual results may vary from the information contained in this presentation due to changes in government policies, regulations, economics reforms, natural calamities, competition, technology, etc. The company is not under any obligation to provide any update or alter forward looking statements, whether as a result of any new information or future events.

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Company

Overview

Zota Healthcare At a Glance

• Zota Health Care Ltd., a publicly listed company on NSE, has established a

significant footprint in the Indian healthcare sector since its inception in 2000.

Business Verticals

• Headquartered in Surat and employing over 470 dedicated professionals, Zota

Health Care Ltd. has seen significant growth over the years, solidifying its strong

presence in the Indian healthcare market.

• Davaindia, launched in 2017, is a retail generic pharmacy chain that provides quality

generic medicines consisting of 2,000+ SKUs.

• The strategic business model allows Davaindia to be both backward and forward

integrated, ensuring control of the entire product life cycle.

Financial Highlights

(9MFY25 - Consolidated)

Total Revenue

₹ 19,570.1 lakhs

Gross Profit

₹ 10,627 lakhs

Gross Merchandise Value

₹ 16,880 lakhs

Davaindia

Domestic

2,000+

SKU’s in Davaindia portfolio

1,413

Operational Davaindia Stores*

4,000+ Products covering major

therapeutic segments 1,050+ Distributors currently, present across India

WHO Recognized

manufacturing partners

Exports

Everyday Herbal Group

30+

Exports markets served

250+ Formulations

manufactured for exports

284 Product approvals received out

of 586 dossiers applications

▪ 56% stake in Everyday Herbal Group strengthens Zota Health Care’s supply chain and product development capabilities

▪ Expands the product portfolio in

the high-revenue over-the-counter (OTC) categor

*As of 28th January 2025

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Our Journey

2000

2004

2010

2011 Commenced exports,

Zota Health Care -

Acquired all brand names

Inaugurated an export-

Incorporated

of Sayona Medicare via an

oriented formulations

expanding business to

MOU

manufacturing unit in

African countries

2007 Acquired Mexon Health Care Limited's

trademark and brand, including Health Park

Laboratories and Aaron Biotech divisions

2010

Zota Pharmaceuticals and Atoz Pharmaceuticals

merged with Zota Health Care

Sachin, SEZ

2012

2013

Secured WHO-GMP

Acquired trademark and

approval for the

brand names of Redix

manufacturing unit at SEZ

Lifecare

2014 Obtained regulatory

2017 Received regulatory

approvals from Kenya (PPB)

approval for SEZ plant

and Sri Lanka (CDDA) for

from Tanzania (TFDA)

the Sachin SEZ plant

Listed on NSE - SME

FOUNDATIONAL STEPS IN

DOMESTIC MARKETING

SETTING UP FORMULATIONS

EXPORT BUSINESS

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

2017

2018

Introduced Davaindia, a private

sector generic pharmacy,

through three pilot outlets

2019

Achieved ₹10+ Cr in Export Sales;

& 75+ Davaindia stores

2020

With over 250 outlets, Davaindia

Opened ~150 Davaindia outlets

became the largest and fastest

Migrated to the Main Board

of NSE

2021

Inception of COCO stores

2023

Total Davaindia stores reaching 600

growing private sector generic

pharmacy chain

2022

Davaindia secured its position as India’s

largest private sector generic pharmacy with

over 500 locations nationwide

2024

Everyday Herbal Group – 56% stake

acquired, licensed by Khadi and Village

Industrial Commission, Government of India.

STRENGTHENING CORE AND

PIONEERING DAVAINDIA

Management Profile ( 1 /2 )

K E TAN K U M AR Z O TA

C H A I R M A N A N D

N O N - E X E C U T I V E D I R E C T O R

Total Experience: 38+

• Holds a D-Pharmacy degree

• Won ‘Lifetime Achievement Award’ from DCGI &

the title of ‘Pharma Ratna Asia’.

M O X E S H Z O TA

M A N A G I N G D I R E C T O R

S U J I T PAU L

G r o u p C h i e f E x e c u t i v e O f f i c e r

Total Experience: 10+

Total Experience: 23+

• Holds a Bachelor’s degree in pharmacy & Master’s

• Featured on Times Now and Brand Vision

degree in international marketing & business management, BPP University in UK

• Under his guidance, company has established a

global presence in 30+ countries

• Honored among Asia One's Top 100 Global

leaders

• Last stint was with Reliance Retail as Vice

President and also worked with Apollo Pharmacy, StayHappi, Columbia Asia Hospitals, etc.

H I M AN S H U Z O TA

W H O L E T I M E D I R E C T O R

K AM L E S H Z O TA

W H O L E T I M E D I R E C T O R

V I R E N Z O TA

W H O L E T I M E D I R E C T O R

Total Experience: 30+

Total Experience: 27+

Total Experience: 15+

• Holds a Diploma in Pharmacy degree and a

• Holds a bachelor’s degree in pharmacy

• Holds a bachelor’s degree in Business

Diploma in Computer Application

• Playing a vital role in the planning & implementation of Davaindia project.

• Earlier worked with Torrent Pharma, Unique

Pharmaceuticals Laboratories.

Administration, B.R.C.M. College

• Earlier worked in Franchisee Marketing, where he

gained hands-on experience across various regions of India.

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Management Profile ( 2 /2 )

AD H E E S H M U K H AR J E E

SGM (South & North) –

COCO & FOFO OPERATIONS

R AJ E S H K U M AR

S G M - I n f o r m a t i o n T e c h n o l o g y

P R I T H I S H K U N D U

G M - B2B, PCD & ET HICAL

Total Experience: 17 Years

Total Experience: 21 Years

Past Experience: • Aster Pharmacy- Bangalore

• SWIGGY

•

Tata Communication LTD

• Prism Payment Services

Past Experience: • Sitaram Bhartia Institute of Science and Research

• BLK-MAX Super Speciality Hospital

• Sancheti Hospital, Pune

• Breach Candy Hospital, Mumbai

Total Experience: 19 Years

Past Experience: • Sun Pharmaceuticals Ltd (Ranbaxy Laboratories Ltd

• Sigachi Industries Ltd

• SGA & Nicholas Healthcare Ltd. (Akums Drugs & Pharmaceuticals)

• Emcure Pharmaceuticals

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

P. S R E E K AN T H

SGM - HR & T&D

S I TAR AM A R AJ U

CONSULTANT - IT

Total Experience: 25 Years

Total Experience: 41 Years

Past Experience: • KIMS Hospital - Secunderabad – Hyderabad

• Apollo Pharmacy

• Apollo Hospitals

Past Experience: • Aster Pharmacy- Bangalore

• Apollo Pharmacy

• Birla Corporation LTD

• Heavy Engineering Corporation

Company Structure

Procurement in listed entity

Zota Health Care Limited

(Listed entity)

Step down subsidiary

Supplying products at ALP*

Davaindia

(Davaindia Health Mart Limited)

COCO

(COCO# stores)

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Domestic

Export

FOFO

(Sales to FOFO# stores)

*ALP – Arm's length price

Business Verticals

# COCO – Company-Owned Company-Operated

FOFO – Franchisee-Owned Franchisee-Operated

FOFO Sales through Zota Health Care Limited

COCO Sales through Davaindia Health Mart Limited

Business & Industry Overview

Business Verticals

R E V E N U E C O N T R IB U T I O N ( Q 3 F Y 2 5 )

1 . D A V A I N D I A

Consolidated

• A Retail generic pharmacy chain providing quality generic medicines.

Everyday Herbal Group

Exports

10%

Domestic

24%

Davaindia

63%

• Focuses only on private-label products in:

• Medicinal

• OTC

• Ayurvedic

• Cosmetic and Nutraceutical

Store variants

02 Company Owned Company Operated (COCO) and Franchisee Owned Franchisee Operated (FOFO)

30% – 90% Savings on medicines as compared to branded counterparts

• Key emphasis is on chronic therapies and ailments

Large Store Network*

• One-of-its-kind concept started with 3 pilot stores in 2017

• COCO Stores are large format stores operated through our wholly-

owned subsidiary

707 COCO stores 706 FOFO stores

*As of 28th January 2025

• FOFO Stores are operated on an asset-light franchisee model

100% private labelled products

2 . D O M E S T I C M A R K E T I N G B U S I N E S S

• Procures

finished dosage

forms

from domestic

formulations

manufactures and market them under own portfolio of brands

• Markets the products across the country to the distributors, which,

in turn, cater to retail pharmacies in their respective districts

1,050+ Distributors currently present across India

4,000+ Products covering major therapeutic segments

WHO Partners with WHO recognized manufacturers

3 . E X P O R T S

Davaindia - the retail generic pharmacy chain, has a rising prominence in the overall business and is one of the fastest growing retail generic pharmacy chains in India.

• Commenced manufacturing operations in 2010 at Sachin (SEZ) unit • The unit facilitates production of about 250 diverse formulations • Focus on prioritizing product registrations across all countries, with the company retaining ownership of Marketing Authorizations (MAs) and registrations in these regions.

284 Product approvals out of 586 dossiers applications

30+ Countries’ approval mainly in the semi regulated and regulated markets

Growth led by exclusive foreign distribution network and exclusive MA holding

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

India is amongst the Lowest Public Spenders

17.00%** Population with household spending on health greater than 10% of total household budget.

6.67%# Population with household spending on health greater than 25% of total household budget.

Medicines account for

~70%

of the total out of pocket healthcare expenditure making it the biggest pie in the healthcare costs

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Country comparison*

$12,012

Source: Health Policy and Planning, Volume 37, Issue 9, November 2022 https://academic.oup.com/heapol/article/37/9/1116/6648021

About

77mn

Indian people living with diabetes and a projection of 134 million by 2045 (International Diabetes Federation), this leads to higher healthcare spends*

$671

$166

$74

China

Sri Lanka

India

Source: Epidemiology of type 2 diabetes in India - https://www.ncbi.nlm.nih.gov/

$74.04*

Healthcare spent per-capita in India

Source: *WHO-Global Health Expenditure Database, **World Bank

Case Study – Savings on Davaindia margins

Same Tablet with same molecule

Multiple brands selling same medicine consisting of same molecule manufactured by same manufacturers with different brand names

Company marketed by >

Indian Pharma MNC 1

Indian Pharma MNC 2

Davaindia

Tablet / Medicine Name

Rosuvas – 10 mg

Rosubest - 10

Rosuvastatin 10

Molecule

Generic Type

Margins

Rosuvastatin 10mg

Branded Generic

Trade Generic

Generic

Trade Margins % Big Pharma / Promotions %

30% 60%

70% 20%

25-30% 0

Consumer Price for 10 Tablets

₹ 208

₹ 115

₹ 21

Significant savings in margins

High intermediary margins for other companies leading to much higher consumer price vs Davaindia

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Tablet

Telmisartan 40 mg & Hydrochlorothiazide 12.5 mg

Levocarnitine 500 mg

Rabeprazole 40 mg

Aceclofenac 100 mg, Paracetamol 325 mg & Serratiopeptidase 15 mg

Manufacturer

Same Manufacturer

Marketed By

Foreign Pharma MNC

Davaindia

Indian Pharma MNC

Davaindia

Indian Pharma MNC

Davaindia

Indian Pharma MNC

Davaindia

MRP

₹ 187.9

₹ 25.0

₹ 404.95

₹ 75.0

₹ 202.5

₹ 35.0

₹ 147.48

₹ 35.0

Davaindia Quality Medication at Affordable Prices

Same Quality, Affordable Price

Davaindia sells generic medicines manufactured by the same producers as branded medicines. This ensures equivalent quality at a fraction of the cost.

Lower Margins, More Savings

Our business model focuses on maintaining modest margins of 25-30%, compared to other companies who incorporate a huge margin of up to ~90% for intermediaries. This results in more affordable prices for consumers.

Cutting Out Intermediaries

Our direct-to-consumer approach eliminates the traditional pharma supply chain, reducing overall costs, and resulting in significant savings for customers.

Industry update

Total turnover of Pharmaceuticals in India in the fiscal year 2023-24 was $50.59bn*

The Indian generic drugs market stood at $24.91bn#in 2024 and is expected to grow at a steady compound annual growth rate (CAGR) of 6.02%#

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Source: *Annual Report Department of Pharmaceuticals FY 23-24, # Research Reports- TechSci, Research & Markets.

DAVAINDIA

Davaindia - Retail Pharmacy Chain data

Revolutionizing the generic pharmacy industry with affordable, accessible, quality healthcare solutions

through retail pharmacies’ chain.

*As of 28th January 2025

2000+

SKUs

1,413*

Total no. of stores

707 COCO stores

706 FOFO Stores

2.17+ crores

Happy consumers till date

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

•

Launched in 2017, Davaindia has rapidly grown into India’s leading private-sector generic pharmacy chain starting with 3 stores and expanded to 1,413 active

stores as of January 2025

Fundamentally driven by providing quality generic medicines at substantial discounts - remarkably 30% to 90% lower than their branded counterparts

Focuses exclusively on private-label products in medicinal, OTC, and ayurvedic categories, with a significant emphasis on chronic therapies and ailments

Every 10 hours, a new davaindia store opens to serve customers better

Every 5 hours, a new employment generation.

2 store Variants

• Company-Owned Company-Operated (COCO)

• Franchisee-Owned Franchisee-Operated (FOFO)

23 States

3 Union Territories

Davaindia - Operating Model

Offers a cluster-based store model, optimizing accessibility and convenience for customers across diverse regions

CLUSTER BASED APPROACH

2,000+ SKUs with 70% medicinal products and 30% OTC products, with a special emphasis on chronic ailments such as cardiac, diabetic and thyroid.

COMPREHENSIVE PORTFOLIO

Cloud-based software and AI-based tools for real-time supply chain and operations management

TECHNOLOGY- BASED MODEL

Implementing a hyperlocal model with on-demand delivery of medicines at consumers’ homes

HYPERLOCAL MODEL

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

COCO MODEL (NEW FORMAT STORES) Large-format, walk-in, Company- Owned Company-Operated stores in key metropolitans & cities across the country

EXCLUSIVE SALE 100% of our product portfolio comprises exclusive sales of private-label generic medicines, OTC, and ayurvedic products

BRAND BUILDING Brand building and consumer- facing advertisement and promotional campaigns with Mr. Kapil Dev as the brand ambassador undertaken by Davaindia

FOFO (Franchisee) MODEL Franchisee-Owned Franchisee-Operated stores adhere to an asset-light model, contributing to scalability and accessibility

z o t a h e a

Davaindia - Eliminating traditional supply chain

By sourcing directly from manufacturers and selling straight to consumers,

traditional pharma supply chain is eliminated & the cost benefits are transferred to the consumer

Average consumer price

t h c a r e . c o m

davaindia.com

Doctors

d a v a

~75% savings on Davaindia medicines as compared to branded counterparts on expenses related to retailers, distributors and marketing.

a . c o m

n d

Traditional Pharma

Manufacturer

Pharma Marketing Company

Distributors

Retailers

Consumers

₹ 100 Traditional Pharma

Davaindia Model

Manufacturer

Consumers

₹ 25 Davaindia

Davaindia – What are COCO Stores

COCO stores are modern walk-in stores providing a distinct contrast to traditional counter-based pharmacies enhancing customer satisfaction and loyalty.

Rapid Expansion

& growth

The time required to open a new COCO store has been significantly reduced from 90 days to 75 days, with further plans to reduce it to 60 days. This allows for rapid store expansion and business growth

Profitable

COCO stores have not only been well-received by consumers but have also proven to be more profitable

Strategic Partnership

Partnership with Indian Oil Corporation Limited (IOCL) offers the benefit of increased visibility and reach, as the COCO stores will be located at IOCL petrol pumps.

Smaller Store Size

Average size of a COCO store is 400-500 sq. feet, which is leading to lower rental and maintenance costs. Despite the small size, these stores can offer a wide range of products to cater to different customer needs.

Efficient Inventory Management

With a working capital cycle of 30-40 days, COCO stores can maintain optimal inventory levels, thus reducing storage costs and potential wastage.

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Company-Owned Company-Operated

(COCO)

Davaindia – COCO Stores

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Davaindia - COCO Stores

707

Operational COCO stores

COCO

Company-Owned Company-Operated

Davaindia Health Mart

Operated by wholly-owned subsidiary Davaindia Health Mart Ltd

z o t a h e a

t h c a r e . c o m

davaindia.com

Significant rent rationalization to ₹ 33,000 p.m. in 3rd phase (505 stores) from ₹ 40,000 p.m. in 2nd phase (101 stores) ₹ 82,000 p.m. in 1st phase (100 stores)

n d

✓ Increased cost efficiency

✓ Long-term economic sustainability of

COCO stores

d a v a

a . c o m

142

151

Enhancing Store Economics

States West Bengal Uttar Pradesh Maharashtra Delhi Haryana Kerala Telangana Uttarakhand Gujarat Karnataka Punjab Rajasthan Madhya Pradesh Odisha Pondicherry Total

No. of Stores 151 142 91 73 47 46 32 26 22 22 22 22 8 2 1 707

As of 28th January 2025

Davaindia COCO - KPI’s (1/2)

No. of Stores

Quarterly Footfall

658

494

387

253

154

11.8

8.6

6.9

5.4

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

in lakhs

15.7

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3FY25

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Davaindia COCO - KPI’s (2/2)

Quarterly GMV

₹ lakhs

Avg. Wallet Spend

₹

₹ 3,507

₹ 249

₹ 241

₹ 238

₹ 229

₹ 224

₹ 2,714

₹ 2,050

₹ 1,660

₹ 1,346

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Younger COCO Stores to fuel growth

658 Total COCO Stores

287 COCO Stores <5m

Significant Young Store Network

Many of our stores are relatively new, still in the early stages of their lifecycle.

While currently modest in revenue, expected to grow multiple folds as they mature.

Average monthly Sales of matured stores (15+ months) is ~219%

higher than average monthly Sales of younger stores (<3 months)

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

s e a S y h t n o m e g a r e v A

Average monthly Sales by Store age

• Ongoing Expansion: Our strategy includes continuous addition of new stores,

₹ 219

further expanding our reach to newer markets. This will result in an expanded

customer base.

219%

•

Increased Footfall: As young stores mature and new ones are added, we

anticipate an increase in footfall. This will inevitably contribute to higher revenue

₹ 100

generation.

• Anticipated Exponential Growth: As young stores mature and build out their

customer bases, the income is forecasted to multiply. This implies that our

revenues are on a trajectory of exponential growth.

0-3 Months

15 + Months

Store Age Average monthly Sales rebased to ₹100

Store Opening Lifecycle – COCO

Days

00 02 04 06 08 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54

58 60

62 64 66 68 70

74 76

75 Days

z o t a h e a

t h c a r e . c o m

Registration

Documentation - Online

Signing process

Store layout Planning

Store Execution Process

Software Installation

Process

Inauguration

davaindia.com

d a v a

n d

c o m

Colour + POP+ Furniture installation

Final Store branding design PPT

Applying Drug Licence & Pharmacist Training

Approval Drug Licence

Initial stock Payment & Dispatch

Software Installation

Receiving stock at store

Inauguration

Same Store Growth – 235 Stores

2.43

572

2.60

611

2.61

614

2.85

671

2.99

703

3.03

712

3.11

731

3.18

747

3.32

780

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

c o m

59%

CAGR

Apr-24

May-24

Jun-24

Jul-24

Aug-24

Sep-24

Oct-24

Nov-24

Dec-24

Total GMV (₹ lakhs)

Average Per Store GMV (₹ lakhs)

The average GMV per store increased from ₹2.43 lakhs in April 2024 to ₹3.32 lakhs in December 2024, reflecting robust monthly growth and a strong CAGR trajectory of 59%

Revenue Growth Trajectory of New Stores

1,64,000

1,46,000

1,75,000

1,80,000

2,10,000

2,25,000

2,40,000

1,26,000

1,03,000

76,000

1st Month

2nd Month

3rd Month

4th Month

5th Month

6th Month

7th Month

8th Month

9th Month

10th Month

GMV (₹)

•

A new store's monthly revenue grows significantly from ₹76,000 in Month 1 to ₹2,50,000 by Month 10, showcasing a robust maturation curve

Note: Sale trend basis on the xxx stores which have been opened between February 2024 and December 2024

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

c o m

Davaindia – What are FOFO Stores

Franchisee-Owned Franchisee-Operated (FOFO)

Asset-light franchise model

FOFO stores employ an asset-light franchise model, contributing to the scalability and accessibility of our product offerings.

Smaller Store size

FOFO stores are compact and over-the-counter format stores, typically having an average size of about 200-300 sq.ft.

Enhancing Customer

Experience:

Walk-In FOFO Stores since Q4FY23

Starting Q4FY23, all newly added Franchisee- Owned Franchisee-Operated (FOFO) stores will be made walk-in, aimed at enhancing the shopping experience by allowing customers to interact and familiarize with the products.

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Davaindia - FOFO Stores

706

Operational FOFO stores

145

FOFO

Franchise Owned Franchise Operated

States Uttar Pradesh Odisha West Bengal Madhya Pradesh Gujarat Haryana Maharashtra Delhi Bihar Rajasthan Kerala Tripura Assam Jammu & Kashmir Jharkhand Tamil Nadu Karnataka Punjab Uttarakhand Telangana Arunachal Pradesh Himachal Pradesh Andhra Pradesh Goa Chhattisgarh Total

As of 28th January 2025

No. of Stores 145 94 92 59 48 42 40 33 30 25 13 12 10 10 9 8 8 6 5 5 3 3 3 2 1 706

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Davaindia - FOFO Stores

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Davaindia FOFO - KPI’s (1/2)

No. of Stores

Quarterly Footfall

697

664

8.9

8.1

645

627

607

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

in lakhs

11.3

10.4

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Davaindia FOFO - KPI’s (2/2)

Quarterly GMV

₹ lakhs

Avg. Wallet Spend

₹

₹ 3,161

₹ 2,840

₹ 2,608

₹ 2,328

₹ 2,465

₹ 290

₹ 278

₹ 271

₹ 279

₹ 274

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

OTC Over- the -counter products

Strategic Acquisition as a move towards backward integration

Acquired 56% stake in the Everyday Herbal Group*, licensed by the Khadi and Village Industrial Commission, a strategic move towards backward integration.

~30% SKUs

OTC products make up ~30% of the stock keeping units (SKUs) offered by our company making it an important part of the business

Khadi

MOU with Everyday Herbal Group leverages the REGP license granted by the Government of India, giving additional credibility and leveraging the well-known 'Khadi' mark.

Q3FY25 OTC

Revenue contribution 25%

*Everyday Herbal Beauty Care & Everyday Health And Beauty Care

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

OTC – Products

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Davaindia is Revolutionising the Indian Healthcare Scenario

6,668

60 %

Gross Merchandise Value in Q3FY25

Gross Margin in COCO format

1,413

30-90 %

Fast growing FOFO & COCO store network*

Savings to consumers on Generic medicines

2.62 Lacs sq. ft*

Total Space Stores

25-30 %

Mature COCO Stores EBITDA#

*As on 28th January 2025

# Calculated prior to IND AS 116

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Davaindia Competitive Edge

The USP of Davaindia: Affordable, Trustworthy, and Innovative Pharmacy Solutions

BENEFITS TO THE CUSTOMERS

BENEFITS TO THE FRANCHISEES

Medicines priced at low MRP thereby ensuring affordability for the masses

Store operations and the supply chain efficiently managed by cloud-based software & AI

Private labels offered, helps in building customer trust by ensuring consistency

Widespread marketing activities help in promoting the brand and improving sales

Continuously adding to its product range thereby offering variety

Products procured from WHO & GMP approved plants and quality attested at NABL approved labs

Elimination of distributors ensures timely supply of stock

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Healthy Repeats

Total Average (in %)

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

With a strong base of 80% repeat customers, Davaindia

demonstrates a high level of customer satisfaction and

loyalty.

80%

Repeat Customers

12%

New Customers

08%

Lost Customers

Higher Chronic category share

54%

55%

21%

25%

20%

Chronic

OTC

Other

Chronic

OTC

Other

CATEGORY MIX FY23

CATEGORY MIX FY24

Higher chronic share: A significant 55% of our revenue comes from chronic disease category, signalling high realization and retention rates, reflecting our crucial role in sustaining long-term patient care.

A pronounced emphasis is placed on chronic therapies and ailments such as cardiac, diabetic, thyroid, and neuropsychiatric, resonating with the core healthcare needs of our customers.

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Supply Chain Management

•

The Company has outsourced supply chain management to a third-party warehousing & logistics partner.

• A state-of-art central warehousing & processing center has been built in Surat, in Phase 1.

•

Eventually the Company will replicate such infrastructure across different zones in the country.

Click the link below for more details

Click here

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Domestic Operations

Domestic marketing has been the oldest business vertical for the Company and has

remained its mainstay in the past. Until 2017, this vertical contributed most of the

Company’s revenues. This business vertical distributes generic drugs, OTC products,

and other pharmaceutical products through the Company’s distribution network spread

across India.

1,050+

Distributors spread across India

4,000+

Products in the portfolio

MARKETING VALUE CHAIN

FDF Manufacturers WHO-GMP certified manufacturing partners

Branding Quality check, packaging and branding under the umbrella of Zota brands

Distribution Direct distribution to 1,050+ distributors spread across the country

Retail Pharmacies Ethical marketing, sales distribution and promotional activities undertaken by distributors

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Expor t Operations

Our Exports business vertical, which started in 2010, serves clients in over 30 countries, mainly

in the CIS, Latin America, Africa, and Asia. At its plant in Sachin, SEZ, the Company

manufactures generic formulations for the dossiers it has registered in overseas markets.

At present, the Company has registered over 284 dossiers, while another 302 dossiers have

been filed and are awaiting approval from the relevant regulatory agencies.

250+

284

302

Products manufactured

Dossiers registered

Dossiers pending approval

Countries exported to:

1. Benin 2. Bolivia 3. Cambodia 4. Cameroon 5. Costa Rica 6. Ethiopia 7. Georgia

8. Ivory coast 9. Kenya 10. Mali 11. Myanmar 12. Nepal 13. Nigeria 14. South Africa

15. Sri Lanka 16. Swaziland 17. Tanzania 18. Turkmenistan 19. Uganda 20. Ukraine 21. Uzbekistan

22. Vietnam 23. Zambia 24. Kyrgyzstan 25. Libya 26. Yemen

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Financial

Overview

Management Commentary

“We are delighted to report another strong quarter for Zota Healthcare, as we continue to drive affordable healthcare access through our rapidly growing Davaindia stores. Indian pharmaceutical market is witnessing a significant shift toward generic medicines, driven by their cost-effectiveness, favourable government initiatives, and the increasing prevalence of chronic diseases. This shift aligns perfectly with our vision, and we are well-positioned to lead this transformation.

During the quarter, we added 195 new stores, which includes 164 COCO stores & 31 FOFO stores. To drive sustainable growth, we’re focusing on self-operated COCO stores, with a goal of adding 1,000 more by FY26. On the financial front, we’ve delivered a strong performance: Davaindia GMV rose to ₹6,668 lakhs, footfalls increased to 26.99 lakhs, and Total Consol revenue grew by 54% YoY to ₹7,212 lakhs. Gross profit also saw robust growth of 87% YoY, reaching ₹4,029 lakhs, a testament to our operational strength and customer loyalty.

As we move forward, our focus remains on reaching more communities, expanding our network, and staying true to our vision of making quality healthcare affordable and accessible for all”

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Mr. Ketankumar Zota Chairman

Quar terly Revenue Segmentation

Business Verticals – Consolidated Revenue bifurcation

Davaindia

₹ lakhs

Domestic Operations

₹ lakhs

Export Operations

₹ lakhs

4,591

4,260

1,571

1,586

1,501

2,354

830

655

359

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Q3 FY24

Q2 FY25

Q3 FY25

Q3 FY24

Q2 FY25

Q3 FY25

Q3 FY24

Q2 FY25 Q3 FY25`

Annually Financial Snapshot

Davaindia has driven revenue growth, recording an impressive increase of 59% CAGR since FY22.

Business Verticals – Consolidated Revenue bifurcation

Davaindia

₹ lakhs

Domestic Operations

₹ lakhs

Export Operations

₹ lakhs

12,432

10,356

5,983

5,950

5,689

5,578

4,122

3,014

2,467

4,478

2,004

1,956

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

FY22

FY23

FY24 9MFY25

FY22

FY23

FY24 9MFY25

FY22

FY23

FY24 9MFY25

Major Business Ver tical Performance ( C o n s o l i d a t e d )

₹ in lakhs

Particulars

Revenue from Operation

Cost of Goods Sold

Gross Profit

% Margin

Employee cost

Other expenses

Operational Expenses

Operating Profit (Pre IND AS)

% Margin

Other Income

EBITDA (Pre IND AS)

% Margin

(Consolidated)

Q3 FY25

Business Vertical

Davaindia

Domestic

Exports

4591.5

1542.3

3049.2

66%

2098.1

2637.1

4735.2

-1686

1500.0

1026.5

473.6

32%

112.1

286.6

398.7

74.8

39.9

114.8

829.9

362.0

467.9

56%

118.2

78.6

196.8

271.1

33%

9.6

280.7

34%

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

Profit & Loss Statement ( C o n s o l i d a t e d )

₹ in lakhs

Particulars

Export Sales (SEZ)

Davaindia Sales

Domestic Sales

Everyday Herbal Group

Revenues from Operations

Cost of Goods Sold

Gross Profit

% Margin

Employee cost

Other expenses

Operational Exp

Operating Profit

% Margin

Other Income

EBITDA

% Margin

Depreciation

EBIT

Interest Cost

EBT

Taxes

Profit After Taxes

Q3FY25

829.88

4590.85

1500.65

291.0

7212.4

3,183.2

4,029.2

55.9%

2382.0

2254.2

4636.2

-607.1

-8.4%

50.6

-556.5

-7.7%

1134.5

-1691.0

157.4

-1848.4

-46.1

-1894.5

Q2FY25

Q3FY24

654.7

4260.3

1586.5

225.9

6,727.6

3,125.5

3,602.1

53.5%

2006.4

1682.7

3689.1

-87.0

-1.3%

54.3

-32.8

-0.5%

951.2

-984.0

285.3

-1269.3

-51.2

-1218.1

359.0

2763.1

1571.0

4693.1

2,537.3

2,155.9

45.9%

775.8

1046.8

1822.6

333.3

7.10%

15.1

348.5

7.4%

507.9

-159.5

113.9

-273.3

20.5

-293.8

9MFY25

1956.7

12432.1

4478.0

703.2

19570.1

8942.8

10,627.3

54.3%

6013.0

5434.1

11447.1

-819.8

-4.19%

106.7

-713.2

-3.6%

2888.1

-3601.3

732.5

-4333.8

51.1

-4384.9

z o t a h e a

t h c a r e . c o m

davaindia.com

d a v a

n d

a . c o m

(Consolidated)

FY24

2,003.5

10,355.9

5,689.4

18,048.9

9,670.0

8,378.8

46.4%

3045.1

4578.4

7623.4

755.4

4.2%

115.6

871.0

4.8%

2008.5

-1137.5

478.8

-1616.3

-181.5

-1434.8

9MFY24

1438.0

6074.0

4412.0

13085.3

7390.9

5,694.3

43.5%

1833.7

2956.7

4790.4

903.9

6.91%

69.9

973.9

7.4%

1328.6

-354.8

310.7

-665.5

77.5

-743.0

Thank You

C o n t a c t I n f o r m a t i o n

M r . A s h v i n V a r i y a

" Z O T A H O U S E " , 2 / 8 9 6 , H i r a M o d i S t r e e t , S a g r a m p u r a , S u r a t - 3 9 5 0 0 2 ( G u j a r a t )

c s z o t a @ z o t a h e a l t h c a r e . c o m w w w . z o t a h e a l t h c a r e . c o m

E Y L L P

S i d d e s h C h a w a n - s i d d e s h . c h a w a n @ i n . e y . c o m

A j i t M i s h r a - a j i t . j . m i s h r a @ i n . e y . c o m

w w w . e y . c o m

← All Transcripts ZOTA Stock Page →

Zota Health Care LImited has informed the Exchange about Investor Presentation

Market Movers